GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: BIOD
Neutral

BIODEL INC. (NASDAQ: BIOD) downgraded to Neutral by Ladenburg Thalmann

Friday,  Dec 18, 2015  4:25 PM ET by Betsy O'Brien Harrison

Ladenburg Thalmann downgraded BIODEL INC. (NASDAQ: BIOD) to Neutral. Previously Ladenburg
Thalmann downgraded to BIODEL INC. (NASDAQ: BIOD) to Buy with price target $6 on 05/10/2013, when the stock price was $3.18.

Biodel Inc. (Biodel) is a development-stage specialty pharmaceutical company located in Danbury, Connecticut. The Company is focused on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis. The Company develops product candidates by applying its formulation technologies to existing drugs in order to improve their therapeutic results. The Company?s initial development efforts are focused on peptide hormones. The Company?s advanced product candidate, VIAject, has been studied in two pivotal Phase III clinical trials for the treatment of patients with Type 1 and Type 2 diabetes. Earlier stage product candidates include VIAtab, a sublingual tablet formulation of insulin and two preclinical product candidates for the treatment of osteoporosis. The Company has developed all of its product candidates utilizing its VIAdel technology that allows the Company to study the interaction between peptide hormones and small molecules.

Our Research Department takes a fresh, critical approach to analyzing primary sources and developing proprietary research. Many individuals, institutions, portfolio managers and hedge fund managers, on all levels, have been neglected by brokerage firms ignoring the demands for unbiased research. Ladenburg Thalmann provides a superior branded in-depth research product geared only to action-oriented investment ideas. Ladenburg Thalmann’s proprietary equity research tries to uncover crucial information before the rest of the Street. Our analysts concentrate on uncovered and under-covered stocks and have a small to mid-cap focus. We will not shy away from large cap names as long as we can bring value to our clients through timely, differentiated ideas.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy